Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 4/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.57 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5562879 | 0.94 | GRM2 (0.76) | GRM2CYP3A4GRM3 | |
| SCHEMBL5562647 | 0.92 | GRM2 (0.67) | GRM2CYP3A4GRM3 | |
| SCHEMBL5558833 | 0.90 | GRM2 (0.67) | GRM2CYP3A4GRM3 | |
| SCHEMBL5563807 | 0.89 | CYP3A4 (0.71) | GRM2CYP3A4GRM3 | |
| SCHEMBL5562753 | 0.87 | GRM2 (0.77) | GRM2CYP3A4GRM3 | |
| SCHEMBL5556422 | 0.87 | GRM2 (0.69) | GRM2CYP3A4GRM3 | |
| SCHEMBL5562438 | 0.86 | GRM2 (0.62) | GRM2CYP3A4 | |
| SCHEMBL6490101 | 0.86 | GRM2 (0.87) | GRM2CYP3A4GRM3 | |
| SCHEMBL5564080 | 0.85 | GRM2 (0.77) | GRM2CYP3A4GRM3 | |
| SCHEMBL6484114 | 0.85 | GRM2 (0.69) | GRM2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1474416-B1 | DIHYDROBENZODIAZEPIN-2-ONE-DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | HOFFMANN LA ROCHE (CH) | 2007-09-26 | — | — | EP | disclosed |
| US-6949542-B2 | Dihydro-benzo[b][1,4]diazepin-2-one derivatives | HOFFMAN-LA ROCHE INC. (US) | 2005-09-27 | — | — | US | disclosed |
| US-20030166639-A1 | Dihydro-benzo[b][1,4]diazepin-2-one derivatives | F. HOFFMAN-LA ROCHE AG (CH) | 2003-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166639-A1 | Dihydro-benzo[b][1,4]diazepin-2-one derivatives | CYP1B1, GRIN2B, CYP4B1 | GRM2 140/4885CYP3A4 188/4885GRM3 164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.